proglumetacin has been researched along with Duodenal Diseases in 1 studies
proglumetacin : A carboxylic ester obtained by formal condensation of the carboxy group of indometacin with the hydroxy group of 3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl N(2)-benzoyl-N,N-dipropyl-alpha-glutaminate. Used (as its dimaleate salt) to control pain and inflammation associated with musculoskeletal and joint disorders. Following oral administration, it is metabolised to indometacin and proglumide, a drug with antisecretory effects that helps prevent injury to the stomach lining.
Duodenal Diseases: Pathological conditions in the DUODENUM region of the small intestine (INTESTINE, SMALL).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yanagawa, A | 1 |
| Fukumura, T | 1 |
| Matsui, H | 1 |
| Uemura, H | 1 |
| Endo, T | 1 |
| Nakagawa, T | 1 |
| Mizushima, Y | 1 |
1 trial available for proglumetacin and Duodenal Diseases
| Article | Year |
|---|---|
Possible mechanisms of gastroduodenal mucosal damage in volunteers treated with nonsteroidal antiinflammatory drugs--the usefulness of prodrugs.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Digestive System; Dinoprostone; Double-B | 1992 |